{{Drugbox
| Watchedfields = changed
| verifiedrevid = 443508077
| IUPAC_name = (6''R'',7''R'')-7-{[(2''R'')-2-hydroxy-2-phenylacetyl]amino}-<br />3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-<br />5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic&nbsp;acid
| image = Cefamandole.svg
<!--Clinical data-->
| tradename =  former Mandol
| Drugs.com = {{drugs.com|CONS|cefamandole}}
| MedlinePlus = a601206
| pregnancy_AU = B1
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!--             / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = POM
| legal_US = <!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V -->
| legal_US_comment = Discontinued
| routes_of_administration = [[Intramuscular injection|Intramuscular]], [[intravenous therapy|intravenous]]
<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound = 75%
| metabolism =  
| elimination_half-life = 48 minutes
| excretion = Mostly [[kidney|renal]], as unchanged drug
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 34444-01-4
| CAS_supplemental = {{CAS|42540-40-9}}
| ATC_prefix = J01
| ATC_suffix = DC03
| PubChem = 456255
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB01326
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 401748
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 5CKP8C2LLI
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D02344
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 3480
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1146
<!--Chemical data-->
| C=18 | H=18 | N=6 | O=5 | S=2
| molecular_weight = 462.505 g/mol
| smiles = O=C2N1/C(=C(\CS[C@@H]1[C@@H]2NC(=O)[C@H](O)c3ccccc3)CSc4nnnn4C)C(=O)O
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C18H18N6O5S2/c1-23-18(20-21-22-23)31-8-10-7-30-16-11(15(27)24(16)12(10)17(28)29)19-14(26)13(25)9-5-3-2-4-6-9/h2-6,11,13,16,25H,7-8H2,1H3,(H,19,26)(H,28,29)/t11-,13-,16-/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = OLVCFLKTBJRLHI-AXAPSJFSSA-N
}}
'''Cefamandole''' ([[International Nonproprietary Name|INN]], also known as '''cephamandole''') is a second-generation [[broad-spectrum antibiotic|broad-spectrum]] [[cephalosporin]] [[antibiotic]]. The clinically used form of cefamandole is the [[formate]] [[ester]] '''cefamandole nafate''', a [[prodrug]] which is administered [[wikt:parenteral|parenterally]].  Cefamandole is [[List of withdrawn drugs|no longer available]] in the United States.

The chemical structure of cefamandole, like that of several other cephalosporins, contains an ''N''-methylthiotetrazole (NMTT or 1-MTT) [[side chain]]. As the antibiotic is broken down in the body, it releases free NMTT, which can cause [[hypoprothrombinemia]] (likely due to [[enzyme inhibitor|inhibition]] of the [[enzyme]] [[vitamin K epoxide reductase]])(vitamin K supplement is recommended during therapy) and a reaction with ethanol similar to that produced by [[disulfiram]] (Antabuse), due to inhibition of [[aldehyde dehydrogenase]].

Cefamandole has a broad spectrum of activity and can be used to treat bacterial infections of the skin, bones and joints, urinary tract, and lower respiratory tract. The following represents cefamandole MIC susceptibility data for a few medically significant microorganisms.
* ''Escherichia coli'': 0.12 - 400 μg/ml
* ''Haemophilus influenzae'': 0.06 - >16 μg/ml
* ''Staphylococcus aureus'': 0.1 - 12.5 μg/ml
<ref>http://www.toku-e.com/Assets/MIC/Cefamandole%20sodium%20salt.pdf</ref>

CO<sub>2</sub> is generated during the normal constitution of cefamandole and ceftazidime, potentially resulting in an explosive-like reaction in syringes.<ref name=Goldfrank>{{cite book |author=Stork CM |veditors=Nelson LH, Flomenbaum N, Goldfrank LR, Hoffman RL, Howland MD, Lewin NA |title=Goldfrank's toxicologic emergencies |chapter=Antibiotics, antifungals, and antivirals |chapterurl=https://books.google.com/books?id=cvJuLqBxGUcC&pg=PA847 |publisher=McGraw-Hill |location=New York |year=2006 |pages=847 |isbn=0-07-143763-0 |accessdate=2009-07-03}}</ref>

==See also==
*[[Cefazolin]]
*[[Ceforanide]]

== References ==
{{Reflist}}

{{CephalosporinAntiBiotics}}

[[Category:Acetaldehyde dehydrogenase inhibitors]]
[[Category:Cephalosporin antibiotics]]
[[Category:Enantiopure drugs]]
[[Category:Tetrazoles]]